Home Other Building Blocks 3-Phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine hydrochloride

3-Phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine hydrochloride

CAS No.:
57226-68-3
Catalog Number:
AG00E8Y2
Molecular Formula:
C16H17ClF3NO
Molecular Weight:
331.7605
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%(HPLC)
In Stock USA
United States
$155
- +
Product Description
Catalog Number:
AG00E8Y2
Chemical Name:
3-Phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine hydrochloride
CAS Number:
57226-68-3
Molecular Formula:
C16H17ClF3NO
Molecular Weight:
331.7605
MDL Number:
MFCD01321043
IUPAC Name:
3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;hydrochloride
InChI:
InChI=1S/C16H16F3NO.ClH/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12;/h1-9,15H,10-11,20H2;1H
InChI Key:
GMTWWEPBGGXBTO-UHFFFAOYSA-N
SMILES:
NCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F.Cl
Properties
Complexity:
294  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
331.095g/mol
Formal Charge:
0
Heavy Atom Count:
22  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
331.763g/mol
Monoisotopic Mass:
331.095g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
35.2A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
A method for reliable voluntary oral administration of a fixed dosage (mg/kg) of chronic daily medication to rats. Laboratory animals 20121001
Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. Journal of analytical toxicology 20120901
Simultaneous determination of fluoxetine and norfluoxetine enantiomers using isotope discrimination mass spectroscopy solution method and its application in the CYP2C9-mediated stereoselective interactions. Journal of chromatography. A 20120504
Trace analysis of fluoxetine and its metabolite norfluoxetine. Part II: Enantioselective quantification and studies of matrix effects in raw and treated wastewater by solid phase extraction and liquid chromatography-tandem mass spectrometry. Journal of chromatography. A 20120302
Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry 20120301
Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. Pharmacology 20110901
Trace analysis of fluoxetine and its metabolite norfluoxetine. Part I: development of a chiral liquid chromatography-tandem mass spectrometry method for wastewater samples. Journal of chromatography. A 20110819
S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology 20110601
A validated enantioselective assay for the simultaneous quantitation of (R)-, (S)-fluoxetine and (R)-, (S)-norfluoxetine in ovine plasma using liquid chromatography with tandem mass spectrometry (LC/MS/MS). Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110215
The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochemical research 20110201
The pH-dependent toxicity of basic pharmaceuticals in the green algae Scenedesmus vacuolatus can be explained with a toxicokinetic ion-trapping model. Aquatic toxicology (Amsterdam, Netherlands) 20110117
Effect of chronic fluoxetine treatment on male and female rat erythrocyte and prefrontal cortex fatty acid composition. Progress in neuro-psychopharmacology & biological psychiatry 20101001
Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. Clinical therapeutics 20101001
Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. Journal of clinical psychopharmacology 20100801
Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug metabolism and disposition: the biological fate of chemicals 20100601
Three-phase, liquid-phase microextraction combined with high performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma. Journal of pharmaceutical and biomedical analysis 20100105
Gas chromatography-mass spectrometry detection of a norfluoxetine artifact in hydrolyzed urine samples may falsely indicate tranylcypromine ingestion. Journal of analytical toxicology 20100101
Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation. Arzneimittel-Forschung 20100101
Determination of fluoxetine and norfluoxetine enantiomers in human plasma by polypyrrole-coated capillary in-tube solid-phase microextraction coupled with liquid chromatography-fluorescence detection. Journal of chromatography. A 20091204
Fluoxetine and norfluoxetine revisited: new insights into the electrochemical and spectroscopic properties. The journal of physical chemistry. A 20090910
Paradoxical anxiogenic response of juvenile mice to fluoxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090901
Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. Pharmacology, biochemistry, and behavior 20090501
Enhanced fear responses in mice treated with anabolic androgenic steroids. Neuroreport 20090422
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Current opinion in pharmacology 20090201
Norfluoxetine induces spawning and parturition in estuarine and freshwater bivalves. Bulletin of environmental contamination and toxicology 20081201
Uptake and depuration of the anti-depressant fluoxetine by the Japanese medaka (Oryzias latipes). Chemosphere 20081201
Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons. Brain research 20081106
Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochemical research 20081001
Fatal intoxication with milnacipran. Journal of forensic and legal medicine 20080801
Genetic regulation of behavioral and neuronal responses to fluoxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080501
Simultaneous determination of citalopram, fluoxetine and their main metabolites in human urine samples by solid-phase microextraction coupled with high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis 20080313
The effects of pH on fluoxetine in Japanese medaka (Oryzias latipes): acute toxicity in fish larvae and bioaccumulation in juvenile fish. Chemosphere 20080101
Fluoxetine and norfluoxetine analysis by direct injection of human plasma in a column switching liquid chromatographic system. Journal of separation science 20080101
Hollow-fibre supported liquid membrane extraction for determination of fluoxetine and norfluoxetine concentration at ultra trace level in sewage samples. Journal of separation science 20071001
Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry. Journal of chromatography. A 20070907
On-line sample stacking and short-end injection CE for the determination of fluoxetine and norfluoxetine in plasma: Method development and validation using experimental designs. Electrophoresis 20070901
The distribution of fluoxetine in human fluids and tissues. Journal of analytical toxicology 20070901
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals 20070801
The effects of antidepressants on cyclic AMP-response element-driven gene transcription in a model cell system. Biochemical pharmacology 20070615
Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601
Solid-phase microextraction-liquid chromatography (SPME-LC) determination of fluoxetine and norfluoxetine in plasma using a heated liquid flow through interface. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070301
Evaluation of the influence of protein precipitation prior to on-line SPE-LC-API/MS procedures using multivariate data analysis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070115
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British journal of pharmacology 20061101
Neurosteroids regulate mouse aggression induced by anabolic androgenic steroids. Neuroreport 20061002
Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology 20060601
T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Molecular pharmacology 20060601
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. International clinical psychopharmacology 20060501
Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. British journal of clinical pharmacology 20060201
Comparison of liquid chromatography with fluorescence detection to liquid chromatography-mass spectrometry for the determination of fluoxetine and norfluoxetine in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060118
Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma. Rapid communications in mass spectrometry : RCM 20060101
Bioequivalence testing of a new tablet formulation of generic fluoxetine. European journal of drug metabolism and pharmacokinetics 20060101
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. Journal of chromatography. A 20051209
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic & clinical pharmacology & toxicology 20051101
Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies. Brain research bulletin 20050930
The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochemical pharmacology 20050901
Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. Farmaco (Societa chimica italiana : 1989) 20050401
Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. British journal of pharmacology 20050301
Relative rectal bioavailability of fluoxetine in normal volunteers. Journal of clinical psychopharmacology 20050201
Determination of select antidepressants in fish from an effluent-dominated stream. Environmental toxicology and chemistry 20050201
Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. Arzneimittel-Forschung 20050101
Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. The international journal of neuropsychopharmacology 20041201
Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. Journal of clinical pharmacology 20041101
A rapid HPLC-DAD method for the analysis of fluoxetine and norfluoxetine in plasma from overdose patients. Journal of pharmaceutical and biomedical analysis 20041029
Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes. Naunyn-Schmiedeberg's archives of pharmacology 20040901
Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040525
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040401
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacology 20040401
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. European journal of clinical pharmacology 20040201
Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. Drug metabolism and disposition: the biological fate of chemicals 20040201
Rapid analysis of fluoxetine and its metabolite in plasma by LC-MS with column-switching approach. Analytical and bioanalytical chemistry 20031101
Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics 20031101
Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. American journal of veterinary research 20030801
Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clinical pharmacology and therapeutics 20030401
Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. The Journal of pharmacology and experimental therapeutics 20030301
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205
[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse (New York, N.Y.) 20030201
Direct stereoselective assay of fluoxetine and norfluoxetine enantiomers in human plasma or serum by two-dimensional gas-liquid chromatography with nitrogen-phosphorus selective detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115
Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105
Determination of fluoxetine and norfluoxetine in rat plasma by HPLC with pre-column derivatization and fluorescence detection. Biomedical chromatography : BMC 20030101
Fluoxetine pharmacokinetics in pediatric patients. Journal of clinical psychopharmacology 20021201
Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis. International journal of clinical pharmacology and therapeutics 20021201
Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry 20021112
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Therapeutic drug monitoring 20021001
Estimates of nursing infant daily dose of fluoxetine through breast milk. Biological psychiatry 20020901
Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG : an international journal of obstetrics and gynaecology 20020901
Micellar electrokinetic capillary chromatography for the determination of fluoxetine and its metabolite norfluoxetine in biological fluids. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020405
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. Journal of affective disorders 20020401
Liquid chromatography/tandem mass spectrometry for the determination of fluoxetine and its main active metabolite norfluoxetine in human plasma with deuterated fluoxetine as internal standard. Rapid communications in mass spectrometry : RCM 20020101
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy. Journal of clinical psychopharmacology 20011201
Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biological psychiatry 20011115
Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology 20010901
Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. British journal of clinical pharmacology 20010701
Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. The Journal of pharmacology and experimental therapeutics 20010601
Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. Journal of clinical psychopharmacology 20010601
Sensitive liquid chromatographic-tandem mass spectrometric method for the determination of fluoxetine and its primary active metabolite norfluoxetine in human plasma. Journal of chromatography. A 20010420
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy research 20010401
Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. Journal of clinical psychopharmacology 20010401
Serum concentrations of fluoxetine in the clinical treatment setting. Therapeutic drug monitoring 20010401
Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. Journal of clinical pharmacology 20010401
Effect of alosetron on the pharmacokinetics of fluoxetine. Journal of clinical pharmacology 20010401
Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta pharmacologica Sinica 20010101
Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection. Journal of pharmaceutical and biomedical analysis 19981001
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology 19960801
Delirium during fluoxetine treatment. A case report. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 19931201
Properties